Advertisement
UK markets closed
  • NIKKEI 225

    38,923.03
    +435.13 (+1.13%)
     
  • HANG SENG

    18,403.04
    +323.43 (+1.79%)
     
  • CRUDE OIL

    74.17
    -2.82 (-3.66%)
     
  • GOLD FUTURES

    2,368.30
    +22.50 (+0.96%)
     
  • DOW

    38,447.86
    -238.46 (-0.62%)
     
  • Bitcoin GBP

    54,235.28
    +1,344.14 (+2.54%)
     
  • CMC Crypto 200

    1,451.75
    -16.19 (-1.10%)
     
  • NASDAQ Composite

    16,754.06
    +19.05 (+0.11%)
     
  • UK FTSE All Share

    4,517.03
    -0.05 (-0.00%)
     

Ironwood Pharmaceuticals First Quarter 2024 Earnings: US$0.03 loss per share (vs US$0.30 profit in 1Q 2023)

Ironwood Pharmaceuticals (NASDAQ:IRWD) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$74.9m (down 28% from 1Q 2023).

  • Net loss: US$4.16m (down by 109% from US$45.7m profit in 1Q 2023).

  • US$0.03 loss per share (down from US$0.30 profit in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ironwood Pharmaceuticals Earnings Insights

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 19% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 4 warning signs for Ironwood Pharmaceuticals (1 makes us a bit uncomfortable!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.